GEN Exclusives

More »

GEN News Highlights

More »
Oct 2, 2006

PTC Receives Award for Biowarfare and Bioterrorism Antibacterials

  • PTC Therapeutics(PTC) received a $17.2-million award from the United States Defense Threat Reduction Agency (DTRA) for the discovery and development of small molecule antibacterials against biowarfare or bioterrorism agents.

    “The DTRA award allows us to diversify our pipeline to include antibacterial agents targeting post-transcriptional control mechanisms,” comments Stuart W. Peltz, president and CEO.

    PTC plans to utilize this three-year contract to initiate Phase I trials. In in vitro tests, the lead compounds in PTC’s antibacterial program demonstrated significant activity against several drug-resistant strains of bacteria, including methicillin-resistant and multidrug-resistant Staphylococcus aureus and vancomycin-resistant Enterococci.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Climate Change and Disease

Are the incursions of dengue fever and West Nile virus into North America just the tip of the iceberg of insect-borne diseases that are migrating due to a warming planet?